Source of donor stem cells impacts incidence of bleeding and platelet and RBC transfusion requirements during stem cell transplantation (SCT): results of the phase III sprint trial of intercept pathogen inactivated platelets

Stadtmauer, E.; Goodnough, L. T.; Coutré, Steven; Howard, Frank D.; Lin, Jin‐Sying; Conlan, Maureen G.

doi:10.1016/j.bbmt.2003.12.166

Cited by 3 publications

(82 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The original systematic review identified 51 records that appeared relevant on the basis of their full text or abstract using the original inclusion/exclusion criteria (Butler 2013). Ten studies were identified and included in the previous version of the review (Agliastro 2006; Cazenave 2010; De Francisci 2004; Janetzko 2005; Kerkhoffs 2010; Lozano 2011; McCullough 2004; Simonsen 2006; Slichter 2006; van Rhenen 2003).…”

Section: Resultsmentioning

confidence: 99%

“…For this 2017 update, we have included the previous two ongoing trials in the review (Johansson 2013; Rebulla 2016), for a total of 12 included completed studies (Agliastro 2006; De Francisci 2004; Janetzko 2005; Johansson 2013; Kerkhoffs 2010; Lozano 2011; McCullough 2004; Rebulla 2016; Simonsen 2006; Slichter 2006; van Rhenen 2003), as well as three ongoing trials (EUCTR2015-001035-20-DE; Kerkhoffs 2013; NCT01789762).…”

Section: Resultsmentioning

confidence: 99%

“…We identified duplication of participants through inclusion in more than one study cycle in three Intercept trials (McCullough 2004; Simonsen 2006; van Rhenen 2003). McCullough 2004 reported data from only the first cycle of the study, whilst we extracted the data for van Rhenen 2003 from cycle 1 only, either from the published literature or obtained through direct author contact. In Simonsen 2006, 1 participant out of 20 received both study transfusions on 2 separate occasions.…”

Section: Methodsmentioning

confidence: 99%

“…We attempted to contact the authors of all 12 included trials via email in order to request additional information and data that were either missing or unclear in the published papers. We received additional data for 10 of the 12 included trials (Cazenave 2010; Janetzko 2005; Johansson 2013; Kerkhoffs 2010; Lozano 2011; McCullough 2004; Rebulla 2016; Simonsen 2006; Slichter 2006; van Rhenen 2003). We recorded the number of participants lost to follow-up for each trial.…”

Section: Methodsmentioning

confidence: 99%

See 3 more Smart Citations

Pathogen-reduced platelets for the prevention of bleeding

Estcourt

Malouf

Hopewell

et al. 2017

Cochrane Database of Systematic Reviews

117

View full text Add to dashboard Cite

Background Platelet transfusions are used to prevent and treat bleeding in people who are thrombocytopenic. Despite improvements in donor screening and laboratory testing, a small risk of viral, bacterial, or protozoal contamination of platelets remains. There is also an ongoing risk from newly emerging blood transfusion-transmitted infections for which laboratory tests may not be available at the time of initial outbreak. One solution to reduce the risk of blood transfusion-transmitted infections from platelet transfusion is photochemical pathogen reduction, in which pathogens are either inactivated or significantly depleted in number, thereby reducing the chance of transmission. This process might offer additional benefits, including platelet shelf-life extension, and negate the requirement for gamma-irradiation of platelets. Although current pathogen-reduction technologies have been proven to reduce pathogen load in platelet concentrates, a number of published clinical studies have raised concerns about the effectiveness of pathogen-reduced platelets for post-transfusion platelet count recovery and the prevention of bleeding when compared with standard platelets. This is an update of a Cochrane review first published in 2013. Objectives To assess the effectiveness of pathogen-reduced platelets for the prevention of bleeding in people of any age requiring platelet transfusions. Search methods We searched for randomised controlled trials (RCTs) in the Cochrane Central Register of Controlled Trials (CENTRAL) (the Cochrane Library 2016, Issue 9), MEDLINE (from 1946), Embase (from 1974), CINAHL (from 1937), the Transfusion Evidence Library (from 1950), and ongoing trial databases to 24 October 2016. Selection criteria We included RCTs comparing the transfusion of pathogen-reduced platelets with standard platelets, or comparing different types of pathogen-reduced platelets. Data collection and analysis We used the standard methodological procedures expected by Cochrane. Main results We identified five new trials in this update of the review. A total of 15 trials were eligible for inclusion in this review, 12 completed trials (2075 participants) and three ongoing trials. Ten of the 12 completed trials were included in the original review. We did not identify any RCTs comparing the transfusion of one type of pathogen-reduced platelets with another. Nine trials compared Intercept® pathogen-reduced platelets to standard platelets, two trials compared Mirasol® pathogen-reduced platelets to standard platelets; and one trial compared both pathogen-reduced platelets types to standard platelets. Three RCTs were randomised cross-over trials, and nine were parallel-group trials. Of the 2075 participants enrolled in the trials, 1981 participants received at least one platelet transfusion (1662 participants in Intercept® platelet trials and 319 in Mirasol® platelet trials). One trial included children requiring cardiac surgery (16 participants) or adults requiring a liver transplant (28 participants). All of the other...

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

See 2 more Smart Citations

Pathogen-reduced platelets for the prevention of bleeding

Estcourt

Malouf

Hopewell

et al. 2017

Cochrane Database of Systematic Reviews

117

View full text Add to dashboard Cite

show abstract

“…Twelve studies were excluded because they compared different participant groups (Andrew 1993; Arnold 2006; Bai 2004; Fanning 1995; Gajic 2006; Gerday 2009; Johansson 2007; Julmy 2009; NCT00699621; Reed 1986; Spiess 2004; Vadhan-Raj 2002). Seventy-three studies compared different types of platelet formulations with outcome measures not relevant to the eligibility criteria (Agliastro 2006; Akkök 2007; Anderson 1997; Arnold 2004; Bentley 2000; Blumberg 2002; Blumberg 2004; Blundell 1996; Carr 1990; Corash 2001; Couban 2002; de Wildt-Eggen 2000; Diedrich 2009; Di Pietro 1998; Dumont 2011; Gmür 1983; Goodnough 2001; Goodrich 2008; Grossman 1980; Gurkan 2007; Harrup 1999; Heal 1993; Heddle 1994; Heddle 1999; Heddle 2002; Heddle 2005; Heddle 2009; Higby 1974; ISRCTN01292427; ISRCTN49080246; ISRCTN56366401; Kakaiya 1981; Kerkhoffs 2010; Klumpp 1999; Kluter 1996; Lapierre 2003; Leach 1991; Lee 1989; Lozano 2010; Lozano 2011; Lu 2011; McCullough 2004; Messerschmidt 1988; Mirasol 2010; Murphy 1982; Murphy 1986; NCT01615146; Norville 1994; Norville 1997; Oksanen 1991; Oksanen 1994; Pamphilon 1996; Schiffer 1983; Shanwell 1992; Singer 1988; Sintnicolaas 1981; Sintnicolaas 1982; Sintnicolaas 1995; Slichter 1998; Slichter 2006; Slichter 2010; Solomon 1978; …”

Section: Resultsmentioning

confidence: 99%

Comparison of different platelet count thresholds to guide administration of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation

Estcourt

Stanworth

Dorée

et al. 2015

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

In people with haematological disorders who are thrombocytopenic due to myelosuppressive chemotherapy or HSCT, we found low-quality evidence that a standard trigger level (10 x 10(9)/L) is associated with no increase in the risk of bleeding when compared to a higher trigger level (20 x 10(9)/L or 30 x 10(9)/L). There was low-quality evidence that a standard trigger level is associated with a decreased number of transfusion episodes when compared to a higher trigger level (20 x 10(9)/L or 30 x 10(9)/L).Findings from this review were based on three studies and 499 participants. Without further evidence, it is reasonable to continue with the current practice of administering prophylactic platelet transfusions using the standard trigger level (10 x 10(9)/L) in the absence of other risk factors for bleeding.

show abstract